|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chung HC, Piha-Paul SA, Lopez-Martin J,
Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D,
Gottfried M, et al: Pembrolizumab after two or more lines of prior
therapy in patients with advanced small-cell lung cancer (SCLC):
Results from the KEYNOTE-028 and KEYNOTE-158 studies. Cancer Res.
79:CT0732019.
|
|
3
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Antonia SJ, López-Martin JA, Bendell J,
Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F,
et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent
small-cell lung cancer (CheckMate 032): A multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 17:883–895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hellmann MD, Callahan MK, Awad MM, Calvo
E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G,
Szustakowski JD, et al: Tumor mutational burden and efficacy of
nivolumab monotherapy and in combination with ipilimumab in
small-cell lung cancer. Cancer Cell. 35:3292019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu
ZX and Xu RH: Evaluation of POLE and POLD1 mutations as biomarkers
for immunotherapy outcomes across multiple cancer types. JAMA
Oncol. 5:1504–1506. 2019. View Article : Google Scholar
|
|
14
|
Song Z, Cheng G, Xu C, Wang W, Shao Y and
Zhang Y: Clinicopathological characteristics of POLE mutation in
patients with non-small-cell lung cancer. Lung Cancer. 118:57–61.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stadler ZK, Battaglin F, Middha S,
Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM,
Reidy-Lagunes DL, et al: Reliable detection of mismatch repair
deficiency in colorectal cancers using mutational load in
next-generation sequencing panels. J Clin Oncol. 34:2141–2147.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marcus L, Lemery SJ, Keegan P and Pazdur
R: FDA approval summary: Pembrolizumab for the treatment of
microsatellite Instability-High solid tumors. Clin Cancer Res.
25:3753–3758. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Narayan P, Wahby S, Gao JJ,
Amiri-Kordestani L, Ibrahim A, Bloomquist E, Tang S, Xu Y, Liu J,
Fu W, et al: FDA approval summary: Atezolizumab plus paclitaxel
protein-bound for the treatment of patients with advanced or
metastatic TNBC whose tumors express PD-L1. Clin Cancer Res.
26:2284–2289. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fashoyin-Aje L, Donoghue M, Chen H, He K,
Veeraraghavan J, Goldberg KB, Keegan P, McKee AE and Pazdur R: FDA
approval summary: Pembrolizumab for recurrent locally advanced or
metastatic gastric or gastroesophageal junction adenocarcinoma
expressing PD-L1. Oncologist. 24:103–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sul J, Blumenthal GM, Jiang X, He K,
Keegan P and Pazdur R: FDA approval summary: Pembrolizumab for the
treatment of patients with metastatic non-small cell lung cancer
whose tumors express programmed Death-Ligand 1. Oncologist.
21:643–650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ricciuti B, Cheng ML, Recondo G, Nishino
M, Umeton R, Sholl LM and Awad MM: DNA damage response gene
alterations are associated with high tumor mutational burden and
clinical benefit from programmed death 1 axis inhibition in
non-small cell lung cancer. J Clin Oncol. 37 (Suppl 15):S90772019.
View Article : Google Scholar
|
|
21
|
Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z,
Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, et al: Potential predictive
value of TP53 and KRAS mutation status for response to PD-1
blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res.
23:3012–3024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR Mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in non-small cell lung
cancer: A retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C,
Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of
PTEN promotes resistance to T cell-mediated immunotherapy. Cancer
Discov. 6:202–216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sade-Feldman M, Jiao YJ, Chen JH, Rooney
MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum
H, Blackmon SM, et al: Resistance to checkpoint blockade therapy
through inactivation of antigen presentation. Nat Commun.
8:11362017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arbour K, Shen R, Plodkowski A, Rizvi H,
Ni A, Long N, Halpenny D, Sanchez-Vega F, Rudin C, Riely G and
Hellmann M: MA19. 09 concurrent mutations in STK11 and KEAP1 is
associated with resistance to PD-(L) 1 blockade in patients with
NSCLC despite high TMB. J Thorac Oncol. 13 (Suppl 10):S4242018.
View Article : Google Scholar
|
|
26
|
Kato S, Goodman A, Walavalkar V,
Barkauskas DA, Sharabi A and Kurzrock R: Hyperprogressors after
immunotherapy: Analysis of genomic alterations associated with
accelerated growth rate. Clin Cancer Res. 23:4242–4250. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang F, Ren C, Zhao Q, Shen L, Dai G, Yuan
X, Chen Y, Yang S, Shi J, Hu X, et al: Association of frequent
amplification of chromosome 11q13 in esophageal squamous cell
cancer with clinical benefit to immune check point blockade. J Clin
Oncol. 37 (Suppl 15):S40362019. View Article : Google Scholar
|
|
28
|
Sun S, Liu Y, Eisfeld AK, Zhen F, Jin S,
Gao W, Yu T, Chen L, Wang W, Chen W, et al: Identification of
germline mismatch repair gene mutations in lung cancer patients
with paired tumor-normal next generation sequencing: A
retrospective study. Front Oncol. 9:5502019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Chen G, Li J, Huang YY, Li Y, Lin
J, Chen LZ, Lu JP, Wang YQ, Wang CX, et al: Association of tumor
protein p53 and ataxia-telangiectasia mutated comutation with
response to immune checkpoint inhibitors and mortality in patients
with non-small cell lung cancer. JAMA Netw Open. 2:e19118952019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benson AB, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN guidelines insights: Colon cancer, version
2.2018. J Natl Compr Canc Netw. 16:359–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ettinger DS, Wood DE, Aggarwal C, Aisner
DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac
LR, et al: NCCN guidelines insights: Non-small cell lung cancer,
version 1.2020. J Natl Compr Canc Netw. 17:1464–1472. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haddad RI, Nasr C, Bischoff L, Busaidy NL,
Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, et al:
NCCN guidelines insights: Thyroid carcinoma, version 2.2018. J Natl
Compr Canc Netw. 16:1429–1440. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Armstrong DK, Alvarez RD, Bakkum-Gamez JN,
Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M,
DeRosa M, et al: NCCN guidelines insights: Ovarian cancer, version
1.2019. J Natl Compr Canc Netw. 17:896–909. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goetz MP, Gradishar WJ, Anderson BO,
Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias
AD, et al: NCCN guidelines insights: Breast cancer, version 3.2018.
J Natl Compr Canc Netw. 17:118–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Lupat R, Amarasinghe KC, Thompson
ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and
Gorringe KL: CONTRA: Copy number analysis for targeted
resequencing. Bioinformatics. 28:1307–1313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zehir A, Benayed R, Shah RH, Syed A,
Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, et
al: Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients. Nat Med.
23:703–713. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niu B, Ye K, Zhang Q, Lu C, Xie M,
McLellan MD, Wendl MC and Ding L: MSIsensor: Microsatellite
instability detection using paired tumor-normal sequence data.
Bioinformatics. 30:1015–1016. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Teo MY, Seier K, Ostrovnaya I, Regazzi AM,
Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, et
al: Alterations in DNA damage response and repair genes as
potential marker of clinical benefit from PD-1/PD-L1 blockade in
advanced urothelial cancers. J Clin Oncol. 36:1685–1694. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mehnert JM, Panda A, Zhong H, Hirshfield
K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L,
Kaufman HL, et al: Immune activation and response to pembrolizumab
in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Campbell BB, Light N, Fabrizio D, Zatzman
M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel
KP, et al: Comprehensive analysis of hypermutation in human cancer.
Cell. 171:1042–1056.e10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sanchez-Vega F, Mina M, Armenia J, Chatila
WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia
S, et al: Oncogenic signaling pathways in the cancer genome atlas.
Cell. 173:321–337.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cancer Genome Atlas Network, . Genomic
classification of cutaneous melanoma. Cell. 161:1681–1696. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Govindan R, Ding L, Griffith M,
Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L,
Wallis J, et al: Genomic landscape of non-small cell lung cancer in
smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee W, Jiang Z, Liu J, Haverty PM, Guan Y,
Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al: The mutation
spectrum revealed by paired genome sequences from a lung cancer
patient. Nature. 465:473–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang M, Luo X, Xu S, Liu W, Ding F, Zhang
X, Wang L, Liu J, Hu J and Wang W: Trends in smoking prevalence and
implication for chronic diseases in China: Serial national
cross-sectional surveys from 2003 to 2013. Lancet Respir Med.
7:35–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu CX, Li Y, Obermoeller-McCormick LM,
Schwartz AL and Bu G: The putative tumor suppressor LRP1B, a novel
member of the low density lipoprotein (LDL) receptor family,
exhibits both overlapping and distinct properties with the LDL
receptor-related protein. J Biol Chem. 276:28889–28896. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen H, Chong W, Wu Q, Yao Y, Mao M and
Wang X: Association of LRP1B mutation with tumor mutation burden
and outcomes in melanoma and non-small cell lung cancer patients
treated with immune check-point blockades. Front Immunol.
10:11132019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lan S, Li H, Liu Y, Ma L, Liu X, Liu Y,
Yan S and Cheng Y: Somatic mutation of LRP1B is associated with
tumor mutational burden in patients with lung cancer. Lung Cancer.
132:154–156. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rizvi H, Sanchez-Vega F, La K, Chatila W,
Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N,
et al: Molecular determinants of response to anti-programmed cell
death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in
patients with non-small-cell lung cancer profiled with targeted
next-generation sequencing. J Clin Oncol. 36:633–641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: Results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mahadevan N, Shivadasani P, Nowak J, Awad
M and Sholl L: MA11. 10 Identification of mismatch repair deficient
lung adenocarcinomas using targeted next-generation sequencing. J
Thorac Oncol. 13 (Suppl 10):S3952018. View Article : Google Scholar
|
|
55
|
Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S,
Chen Y and Wu K: Notch signaling and EMT in non-small cell lung
cancer: Biological significance and therapeutic application. J
Hematol Oncol. 7:872014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qiu H, Zmina PM, Huang AY, Askew D and
Bedogni B: Inhibiting Notch1 enhances immunotherapy efficacy in
melanoma by preventing Notch1 dependent immune suppressive
properties. Cancer Lett. 434:144–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang K, Hong X, Song Z, Xu Y, Li C, Wang
G, Zhang Y, Zhao X, Zhao Z, Zhao J, et al: Identification of
deleterious mutation as novel predictor to efficacious
immunotherapy in NSCLC. Clin Cancer Res. 26:3649–3661. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jiang D, Niu Z, Zhang J, Wang Y, Shang L,
Li B, Guo J, Wang B, Zhao LQ, Wang W, et al: Notch family gene
mutations associate with high tumor mutational burden in diverse
cancers. J ClinOncol. 37 (Suppl 15):e146162019. View Article : Google Scholar
|
|
59
|
Severson EA, Ramkissoon S, Daniel S,
Vergilio JA, Gay LM, Elvin JA, Suh J, Frampton GM, Ali SM, Miller
VA and Ross JS: Association of tumor mutational burden in cutaneous
squamous cell carcinoma with genomic alterations in Notch family
receptors. J Clin Oncol. 35 (Suppl 15):e130312017. View Article : Google Scholar
|
|
60
|
Subbiah V, Solit DB, Chan TA and Kurzrock
R: The FDA approval of pembrolizumab for adult and pediatric
patients with tumor mutational burden (TMB) ≥10: A decision
centered on empowering patients and their physicians. Ann Oncol.
31:1115–1118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
